

Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Owner
Owner
Owner
Owner
Owner
Owner
Contributor
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project targets well-characterized aging pathways (DNA damage, epigenetic drift, inflammatory signaling, mitochondrial dysfunction) using single-cell transcriptomic data from ~850,000 transcriptomes across ages 23–91, providing a robust foundation. The identified targets (NR4A1/2, CD38, UHRF1, CCR9, etc.) are biologically relevant and supported by existing literature. However, the score is not a 5 because: (1) all evidence is computational/bioinformatic with zero experimental validation; (2) the multi-modal intervention strategy (simultaneously modulating many targets) adds complexity and uncertainty about which targets are truly causal vs. correlative; and (3) the AubrAI-generated hypothesis, while interesting, is AI-derived and unvalidated, introducing speculative elements into the mechanistic rationale.
Therapeutic Optionality
The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline, anemia, myelodysplastic syndromes, leukemia prevention, chronic inflammation, and broader regenerative medicine applications. The multi-modal intervention approach (mRNA, siRNA, small molecules, CRISPR, gene therapy, nanoparticle delivery) provides flexibility in modality selection. The platform nature of the scRNA-seq/AI pipeline could be applied to other stem cell types beyond HSCs. The project also identifies drug repurposing opportunities (e.g., cromolyn sodium for TPSB2/TPSAB1). A score of 5 is not warranted because the concept remains narrowly focused on HSCs at this stage, and the breadth of therapeutic optionality is theoretical rather than demonstrated.
Intellectual Property
The IP position is moderate. Novelty exists in the specific combination of targets identified through the scRNA-seq aging atlas and the multi-modal intervention framework, which could be patentable as a composition/method. The proprietary datasets and AI/ML-derived target prioritization add some defensibility. However, significant IP risks exist: (1) no patents have been filed or granted yet — IP is entirely aspirational; (2) many individual targets (CD38, RhoA, NR4A, rapamycin, senolytics) are well-known in the aging/hematopoiesis field with extensive prior art; (3) the computational pipeline uses publicly available scRNA-seq data, limiting data exclusivity; (4) several proposed small molecules (Fasudil, rapamycin, cromolyn sodium) are existing drugs with established IP landscapes; (5) competitors in the HSC rejuvenation space (academic and commercial) are active. The combination approach and specific target gene list may offer patentable novelty, but the window for filing is narrowing as the field advances rapidly.